Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
26 Results for "
Fragile
" in MedChemExpress (MCE) Product Catalog:
Products (26)
26 Results for "Fragile" in MCE Product Catalog:
5
5 Cited Publications
Cat. No.: HY-N0794
CAS No.: 20347-71-1
4
Target:
Research Areas:
Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
1
1 Cited Publications
Synonyms: RG7090; RO4917523
Target:
Research Areas:
Basimglurant (RG7090; RO4917523) is a selective, orally active, blood-brain barrier permeable negative allosteric modulator of metabotropic glutamate receptor 5 (mGluR5), with a Ki of 1.4 nM (against [ 3H]-ABP688 (HY-110141)) and 35.6 nM (against [ 3H]-MPEP (HY-14609A)). Basimglurant inhibits mGlu5-mediated signaling pathways and receptor constitutive activity, regulates dopamine levels in the nucleus accumbens, exerts anxiolytic, antidepressant-like, analgesic and arousal-promoting effects, and alters δ-wave power during non-rapid eye movement sleep. Basimglurant can be used in research on depression, fragile X syndrome, anxiety disorders, etc .
1
Target:
Research Areas:
HTL14242 (HTL0014242) is an advanced and orally active mGlu5 NAM with a pKi and a pIC50 of 9.3 and 9.2, respectively . HTL14242 can be used for the research of parkinson’s disease .
Synonyms: RG-7816; RO-7017773
Target:
Research Areas:
Alogabat is a positive allosteric modulator (PAM) and agonist (Ki <100 nM) of the GABAA α5 receptor, targeting the α5β3γ2 subunit with a Ki of 8.7 nM. Alogabat increases the expression level of α5β3γ2 in oocytes (1.97-fold). GABAA has been implicated in cognitive impairment associated with central nervous system (CNS) disorders, brain cancer (including brain tumors such as medulloblastoma), and can be used in the study of mild cognitive impairment (MCI), amnestic MCI (aMCI), age-associated memory impairment (AAMI), age-related cognitive decline (ARCD), dementia, Alzheimer's disease (AD), prodromal AD, post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cognitive impairment associated with cancer treatment, mental retardation, Parkinson's disease (PD), autism spectrum disorder, fragile X, Rett syndrome, obsessive-compulsive behavior, and substance addiction .
Category:
Target:
Cat. No.: HY-170781
CAS No.: 3099003-91-2
Target:
Research Areas:
MDI-114215 (compound 85) is an allosteric LIMK1/2 dual inhibitor with good in vivo tolerance. MDI-114215 can inhibit cofilin phosphorylation in mouse brain region-induced pluripotent stem cells (iPSCs), which can be used for Fragile X Syndrome (FXS) research .
Target:
Research Areas:
ACDPP is a specific mGluR5 antagonist. ACDPP partially bolcks the increase of fragile X mental retardation protein (FMRP) caused by DHPG (HY-12598A) (group I mGluR Agonist) .
Cat. No.: HY-145996
CAS No.: 401513-39-1
Target:
Research Areas:
STC314 is a histone-neutralizing agent. STC314 inhibits histone-mediated cytotoxicity, blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes. STC314 reduces histone-mediated tissue damage, thrombocytopenia, anemia, and cell death, and improves survival in preclinical models. STC314 can be used for the research of sepsis, ischemia-reperfusion injury, and deep-vein thrombosis .
Cat. No.: HY-W773779
CAS No.: 748145-12-2
Target:
Research Areas:
GSK3-IN-9 (Compound 0713) is a selective glycogen synthase kinase 3 (GSK3) inhibitor. GSK3-IN-9 Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder .
Cat. No.: HY-174229
Target:
Research Areas:
SM311 (Compound 10), a chemical probe, is a potent selective irreversible LIMK1 inhibitor (EC50=0.045 μM, >30-fold selective over LIMK2). SM311 blocks cofilin phosphorylation and actin cytoskeleton regulation. SM311 is promising for research of neurodegenerative diseases like Fragile X syndrome (FXS) and Alzheimer’s disease, as well as tumor invasion .
Cat. No.: HY-N4145
CAS No.: 86631-39-2
Synonyms: Cinnamtannin A3; Cinnamtannin II
Target:
Cat. No.: HY-129159R
CAS No.: 2364-23-0
Target:
Cat. No.: HY-121503
CAS No.: 68207-21-6
Target:
Research Areas:
FD44 is a phenothiazine small molecule that inhibits the interaction between neuronal calcium sensor 1 (NCS-1) and the guanine exchange factor Ric8a, a key regulator of synapse number and neurotransmitter release probability. In the Drosophila genetic autism model of fragile X syndrome (FXS), FD44 restored normal synapse number and associative learning .
Cat. No.: HY-155238
CAS No.: 1520073-91-9
Target:
Research Areas:
E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) .
Cat. No.: HY-176856
CAS No.: 2748705-69-1
Target:
Research Areas:
Maxi-K modulator 1 (Example 1) is a Maximum conductance calcium-activated potassium (Maxi-K) channel modulator. Maxi-K modulator 1 has a potent stimulating effect on Maxi-K channel activity. Maxi-K modulator 1 can be used for fragile X syndrome research .
Cat. No.: HY-148717
CAS No.: 159357-82-1
Target:
Research Areas:
NSC363998 (free base) is an orally active compound. NSC363998 (free base) can suppress rCGG90 induced neurotoxicity. NSC363998 (free base) can be used for the research of neurodegenerative disorder such as Fragile X associated tremor/ataxia syndrome (FXTAS) .
Cat. No.: HY-15257R
CAS No.: 543906-09-8
Synonyms: AFQ056 (Standard)
Target:
Research Areas:
Mavoglurant (Standard) is the analytical standard of Mavoglurant. This product is intended for research and analytical applications. Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease . Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Cat. No.: HY-N16480
CAS No.: 651750-97-9
Synonyms: Lindetannin trimer
Target:
Cat. No.: HY-181828
Target:
Research Areas:
SePP is a blood-brain barrier-permeable NMDAR antagonist and dopamine/norepinephrine reuptake inhibitor, with a Ki of 28.7 nM for rat NMDAR. SePP exerts anticonvulsant effects. SePP can be used in research related to fragile X syndrome .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
